Genetic predisposition of life-threatening antiepileptic-induced skin reactions

Expert Opinion on Drug Safety

Volumn 9, Issue 1, 2010, Pages 15-21

  Chung, Wen Hung ^b   Hung, Shuen Iu ^a,c   Chen, Yuan Tsong ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Adverse drug reactions; Antiepileptic drugs; Carbamazepine, oxcarbazepine; Personalized medicine; Phenytoin; Preventive medicine; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; FOSPHENYTOIN SODIUM; HLA B ANTIGEN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN;

ALLELE; ATAXIA; BIPOLAR DISORDER; BONE MARROW TOXICITY; CENTRAL NERVOUS SYSTEM DEPRESSION; CEREBELLUM DISEASE; CHINESE; CROSS REACTION; DIPLOPIA; DRESS SYNDROME; DRUG LABELING; DRUG STRUCTURE; DRUG WITHDRAWAL; EPILEPSY; ETHNIC GROUP; FOOD AND DRUG ADMINISTRATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HEPATITIS; HIGH RISK POPULATION; HUMAN; MACULOPAPULAR RASH; MORBIDITY; MORTALITY; NYSTAGMUS; PHENOTYPE; PSEUDOLYMPHOMA; REVIEW; SEDATION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN MANIFESTATION; SOUTHEAST ASIA; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TRIGEMINUS NEURALGIA;

ANTICONVULSANTS; CARBAMAZEPINE; CONTINENTAL POPULATION GROUPS; DRUG LABELING; EPIDERMAL NECROLYSIS, TOXIC; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HLA-B ANTIGENS; HUMANS; SKIN DISEASES; STEVENS-JOHNSON SYNDROME;

EID: 74349120713     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330903427969     Document Type: Review

References (43)

1. Toledano R, Gil-Nagel A. Adverse effects of antiepileptic drugs. Semin Neurol 2008;28:317-327 .
2. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005;209:123-129 .
3. Kennedy GM, Lhatoo SD. CNS adverse events associated with antiepileptic drugs. CNS Drugs 2008;22:739-760
4. Gogtay NJ, Bavdekar SB, Kshirsagar NA. Anticonvulsant hypersensitivity syndrome: A review. Expert Opin Drug Saf 2005;4:571-581
5. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007;48:1223-1244
6. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003;139:683-693 .
7. Krivoy N, Taer M, Neuman MG. Antiepileptic drug-induced hypersensitivity syndrome reactions. Curr Drug Saf 2006;1:289-299
8. Kaufman DW, Shapiro S. Epidemiological assessment of drug-induced disease. Lancet 2000;356:1339-1343
9. Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007;68:1701-1709 .
10. Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: Influence by gender, age, and learning disability. Epilepsia 2007;48:1360-1365
11. Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity syndrome: Implications for pharmaceutical care. Pharmacotherapy 2007;27:1425-1439
12. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: A clinical classification. J Invest Dermatol 1994;102:28S-30S .
13. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008;14:1343-1350
14. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. J Neurology 2005;64:1134-1138
15. Hung SI, Chung WH, Chen YT. HLA-B genotyping to detect carbamazepine-induced Stevens-Johnson syndrome: Implications for personalizing medicine. Personalized Med 2005;2:225-237 .
16. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008;128:35-44
17. Amann B, Grunze H, Vieta E, Trimble M. Antiepileptic drugs and mood stability. Clin EEG Neurosci 2007;38:116-123
18. Ziegler D. Painful diabetic neuropathy: Treatment and future aspects. Diabetes Metab Res Rev 2008;24(Suppl 1):S52-7
19. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005;64:1134-1138
20. Farkas R, Clinical review, adverse events of carbamazepine. 2009 Available from URL: http://www.fda.gov/cder/foi/nda/ 2007/016608s098,020712s029, 021710-ClinRev.pdf
21. Chung WH, Hung SI, Hong HS, et al. Medical genetics: A marker for Stevens-Johnson syndrome. Nature 2004;428:86 .
22. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006;16:297-306 .
23. Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007;48:1015-1018
24. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008;49:2087-2091
25. Chang CC, Too CL, Murad S, Hussein S. Association of HLA-B*1502 with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in Malaysian population. Proceeding in 7th Asian- Oceanian Epilepsy Congress, Xiamen; 2008
26. Kaniwa N, Saito Y, Aihara M, et al; JSAR research group. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008;9:1617-1622
27. Lonjou C, Thomas L, Borot N, et al; RegiSCAR Group. A marker for Stevens-Johnson syndrome: Ethnicity matters. Pharmacogenomics J 2006;6:265-268 .
28. Lonjou C, Borot N, Sekula P, et al; RegiSCAR study group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008;18:99-107 .
29. Alfirevic A, Jorgensen AL, Williamson PR, et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006;7:813-818 .
30. Daar AS, Singer PA. Pharmacogenetics and geographical ancestry: Implications for drug development and global health. Nat Rev Genet 2005;6:241-246
31. Website: Allele Frequencies. Available from: http://www. allelefrequencies.net/
32. Hung SI, Chung WH, Chen YT. Genetics of severe drug hypersensitivity reactions in Han Chinese. In: Pichler WJ, editor, Drug Hypersensitivity. Karger, Medical and Scientific Publishers. Bern, Switzerland; 2007. p. 55-64
33. Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007;7:317-323
34. FDA ALERT: Dangerous or even fatal skin reactions - carbamazepine (marketed as carbatrol, equetro, tegretol, and generics) - healthcare professional sheet text version. Available from: http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/ ucm124718.htm
35. Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008;9:1543-1546 .
36. Romano A, Guéant-Rodriguez RM, Viola M, et al. Cross-reactivity among drugs: Clinical problems. Toxicology 2005;209:169-179
37. Romano A, Pettinato R, Andriolo M, et al. Hypersensitivity to aromatic anticonvulsants: In vivo and in vitro cross-reactivity studies. Curr Pharm Des 2006;12:3373-3381
38. Hirsch LJ, Arif H, Nahm EA, et al. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology 2008;71:1527-1534 .
39. Alvestad S, Lydersen S, Brodtkorb E. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs. Epilepsy Res 2008;80:194-200
40. Seitz CS, Pfeuffer P, Raith P, et al. Anticonvulsant hypersensitivity syndrome: Cross-reactivity with tricyclic antidepressant agents. Ann Allergy Asthma Immunol 2006;97:698-702
41. Chen YC, Chu CY, Hsiao CH. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype. J Eur Acad Dermatol Venereol 2009;23:702-703
42. Lin LC, Lai PC, Yang SF, Yang RC. Oxcarbazepine-induced Stevens-Johnson syndrome: A case report. Kaohsiung J Med Sci 2009;25:82-86
43. Kazeem GR, Cox C, Aponte J, et al. High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet Genomics 2009;19:661-665